Sclerotherapy With Polidocanol Is Highly Effective for Treating Oral Cavernous Hemangiomas in Children.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14006

Li-Na Han, Yu-Bo Wang, Rong-Xiang Tian, Wen-Ya Huang, Ralf Smeets, Martin Gosau, Lan Kluwe, Ming Yan, Rico Rutkowski, Reinhard E Friedrich

{"title":"Sclerotherapy With Polidocanol Is Highly Effective for Treating Oral Cavernous Hemangiomas in Children.","authors":"Li-Na Han, Yu-Bo Wang, Rong-Xiang Tian, Wen-Ya Huang, Ralf Smeets, Martin Gosau, Lan Kluwe, Ming Yan, Rico Rutkowski, Reinhard E Friedrich","doi":"10.21873/invivo.14006","DOIUrl":null,"url":null,"abstract":"Background/aim: Cavernous hemangiomas in children older than 2 years will unlikely resolute and therefore, frequently require treatment. The aim of the study was to comparatively evaluated the outcome of the sclerotherapy with polidocanol and the conventional pingyangmycin therapy for thick cavernous hemangiomas in the oral cavity in children.Patients and methods: We treated a total of 21 cavernous hemangiomas in the oral cavity (majority on the tongue) of children aged 2-11 years by means of a sclerotherapy using an anesthetic agent polidocanol under ultra-sound monitoring.Results: Total regression of the tumors was achieved in 20 cases, corresponding to a success rate of 95%, significantly (p=0.0005) higher than that achieved by the conventional pingyangmycin therapy, which was <50%. No severe complication was observed, while mild and transit ones such as local swelling, pain, and ulceration were reported by both groups at similar frequency (10-20%).Conclusion: Sclerotherapy using polidocanol provides an effective, safe, and relatively simple treatment for hemangiomas in the oral cavity of children and may be recommended to replace the conventional pingyangmicine treatment.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2109-2114"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223627/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Cavernous hemangiomas in children older than 2 years will unlikely resolute and therefore, frequently require treatment. The aim of the study was to comparatively evaluated the outcome of the sclerotherapy with polidocanol and the conventional pingyangmycin therapy for thick cavernous hemangiomas in the oral cavity in children.

Patients and methods: We treated a total of 21 cavernous hemangiomas in the oral cavity (majority on the tongue) of children aged 2-11 years by means of a sclerotherapy using an anesthetic agent polidocanol under ultra-sound monitoring.

Results: Total regression of the tumors was achieved in 20 cases, corresponding to a success rate of 95%, significantly (p=0.0005) higher than that achieved by the conventional pingyangmycin therapy, which was <50%. No severe complication was observed, while mild and transit ones such as local swelling, pain, and ulceration were reported by both groups at similar frequency (10-20%).

Conclusion: Sclerotherapy using polidocanol provides an effective, safe, and relatively simple treatment for hemangiomas in the oral cavity of children and may be recommended to replace the conventional pingyangmicine treatment.

查看原文本刊更多论文

多元醇硬化疗法治疗儿童口腔海绵状血管瘤疗效显著。

背景/目的：海绵状血管瘤在大于2岁的儿童中不太可能发生，因此经常需要治疗。本研究的目的是比较评价聚多卡因硬化疗法与常规平阳霉素治疗儿童口腔厚海绵状血管瘤的疗效。患者和方法：我们在超声监测下使用麻醉剂poly - canol进行硬化治疗，共治疗21例2-11岁儿童口腔海绵状血管瘤（大部分在舌头上）。结果：肿瘤完全消退20例，成功率为95%，显著（p=0.0005）高于常规平阳霉素治疗。结论：聚多卡因硬化治疗儿童口腔血管瘤是一种有效、安全且相对简单的治疗方法，可推荐替代常规平阳霉素治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.